Healthcare / Medical DevicesNYSE
$5.49
-0.04 (-0.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-12.0M · quality 56.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
33/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$159M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-111.9%
↓Gross Margin
50.6%
↑Debt/Equity
0.37
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+7.0%
FCF CAGR
—
FCF margin
-11.1%
FCF / Net income
0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $105.7M · net income $-39.7M · FCF $-11.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $105.7M | $105.7M | $78.1M | $54.0M | $69.2M | $75.8M | $75.4M |
| Net Income | $-39.7M | $-39.7M | $-12.5M | $-32.9M | $-79.3M | $-71.7M | $-10.5M |
| EBITDA | $-35.6M | $-35.6M | $-9.5M | $-27.5M | $-75.5M | $-54.7M | $-6.1M |
| EPS | — | — | -1.57 | -4.53 | -9.94 | -15.82 | -6.72 |
| Gross Margin | 50.6% | 50.6% | 50.4% | 41.8% | 33.7% | 46.2% | 47.6% |
| Operating Margin | -7.8% | -7.8% | -25.9% | -53.0% | -122.3% | -73.6% | -9.3% |
| Net Margin | -37.5% | -37.5% | -16.1% | -60.9% | -114.6% | -94.5% | -14.0% |
| Balance Sheet | |||||||
| Debt/Equity | 0.37 | 0.37 | -0.70 | -0.51 | -1.52 | 0.14 | -0.15 |
| Current Ratio | 1.71 | 1.71 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-11.7M | $-11.7M | $-12.0M | $-23.6M | $-82.9M | $-41.5M | $-1.1M |
| Returns | |||||||
| ROE | -111.9% | -111.9% | 74.6% | 110.9% | 746.0% | -129.9% | 15.5% |
| Valuation | |||||||
| P/B | 4.17 | 4.17 | — | — | — | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 35.4% | 35.4% | 44.5% | -22.0% | — | 0.6% | — |
| EPS Growth | — | — | 65.3% | 54.4% | — | -135.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+1.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.57 → n/d
Residual
+1.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.